WHO advises against anti-obesity drugs for children under 10

The news currently comes from a single source (KFF Health News, which cites the World Health Organization guideline, also reported by Bloomberg); no further independent confirmation is available in the excerpts at hand.

The World Health Organization has issued a recommendation against the use of anti-obesity drugs in children under 10. The reason given by the agency concerns uncertainty over long-term effects: it is not clear, according to the WHO, how drugs described as powerful might affect the bodies of such young children over time. The guideline does not go, in the excerpts available, into detail on individual active substances nor does it cite specific studies in support: the recommendation is reported as the agency’s institutional position, not as a summary of a specific piece of research.

For the next age group, between 10 and 19 years old, the indication changes but remains restrictive: according to the United Nations agency, medication represents an option only in cases where lifestyle change programs, conducted under medical supervision, have not produced results. It is not, therefore, an outright negative recommendation for adolescents, but an indication that places medication as a last resort, not a first choice. The distinction by age group is the central point of the guideline: the WHO does not treat childhood obesity as a single block, but clearly separates childhood from adolescence in its indications.

For this age group the WHO strongly recommends, as the primary approach, healthy eating and physical exercise. This is an institutional recommendation attributed to the agency, not advice formulated by this publication: the distinction between the two is not merely editorial, because it entirely determines what can and cannot be written on a subject of this kind.

The guideline, overall, draws a clear line by age: under 10, medication is advised against with no exceptions indicated in the excerpts available; between 10 and 19, it becomes a residual option, subordinate to the failure of supervised non-pharmacological approaches. It remains to be seen, with further sources, how the recommendation will be adopted by national health systems.